{
    "organizations": [],
    "uuid": "3953f219d9821633260a4fd3e2ed2d9374272b16",
    "author": "",
    "url": "https://www.reuters.com/article/brief-medicenna-amends-protocol-of-phase/brief-medicenna-amends-protocol-of-phase-2b-recurrent-glioblastoma-study-of-mdna55-idUSFWN1S90NF",
    "ord_in_thread": 0,
    "title": "BRIEF-Medicenna Amends Protocol Of Phase 2B Recurrent Glioblastoma Study Of MDNA55",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 2, 2018 / 11:08 AM / Updated 10 minutes ago BRIEF-Medicenna Amends Protocol Of Phase 2B Recurrent Glioblastoma Study Of MDNA55 Reuters Staff 1 Min Read\nMay 2 (Reuters) - Medicenna Therapeutics Corp:\n* MEDICENNA AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY OF MDNA55 IN RESPONSE TO STRONG SAFETY DATA AND EARLY EFFICACY READ-OUTS\n* MEDICENNA THERAPEUTICS - AMENDS PROTOCOL OF PHASE 2B RECURRENT GLIOBLASTOMA STUDY WILL EXTEND EXPECTED TIMING TO COMPLETE ENROLLMENT IN STUDY TO Q42018\n* MEDICENNA THERAPEUTICS CORP - HALF PATIENTS IN ONGOING PHASE 2B STUDY OF MDNA55 IN RECURRENT GLIOBLASTOMA (RGBM) HAVE BEEN RECRUITED Source text for Eikon: Further company coverage:",
    "published": "2018-05-02T14:07:00.000+03:00",
    "crawled": "2018-05-02T14:25:57.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "updated",
        "minute",
        "ago",
        "amends",
        "protocol",
        "phase",
        "2b",
        "recurrent",
        "glioblastoma",
        "study",
        "mdna55",
        "reuters",
        "staff",
        "min",
        "read",
        "may",
        "reuters",
        "medicenna",
        "therapeutic",
        "corp",
        "medicenna",
        "amends",
        "protocol",
        "phase",
        "2b",
        "recurrent",
        "glioblastoma",
        "study",
        "mdna55",
        "response",
        "strong",
        "safety",
        "data",
        "early",
        "efficacy",
        "medicenna",
        "therapeutic",
        "amends",
        "protocol",
        "phase",
        "2b",
        "recurrent",
        "glioblastoma",
        "study",
        "extend",
        "expected",
        "timing",
        "complete",
        "enrollment",
        "study",
        "q42018",
        "medicenna",
        "therapeutic",
        "corp",
        "half",
        "patient",
        "ongoing",
        "phase",
        "2b",
        "study",
        "mdna55",
        "recurrent",
        "glioblastoma",
        "rgbm",
        "recruited",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}